CIK 0001620463 · Non-accelerated filer<br>Smaller reporting company
LeonaBio, Inc.
Sign in to watch- Ticker
- LONA
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Entity type
- operating
- EIN
- 453368487
- Phone
- (425) 620-8501
- Business address
- 18706 NORTH CREEK PARKWAY, SUITE 104, BOTHELL, WA, 98011
- Former names
- Athira Pharma, Inc., M3 Biotechnology, Inc.
- Open-market buys, last 90 days
- $9,919,161,281
- in 1 filing
- Open-market sales, last 90 days
- $0
- in 0 filings
Net +$9,919,161,281. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 85 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-10-01 | Worthington Mark General Counsel and CCO | Grant or award · Stock Option (Right to Buy) | +110,000 | 110,000 | ||
| 2024-09-05 | Gengos Andrew CFO and Chief Business Officer | Sale | −1,272 | $0.57 | $720 | 97,532 |
| 2024-09-05 | Lenington Rachel COO and CDO | Sale | −2,525 | $0.57 | $1K | 20,870 |
| 2024-09-05 | CHURCH KEVIN CHIEF SCIENTIFIC OFFICER | Sale | −2,525 | $0.57 | $1K | 92,684 |
| 2024-09-05 | Worthington Mark GENERAL COUNSEL | Sale | −2,525 | $0.57 | $1K | 51,927 |
| 2024-09-05 | Litton Mark James President and CEO | Sale | −5,032 | $0.57 | $3K | 159,365 |
| 2024-09-03 | Gengos Andrew CFO and Chief Business Officer | Grant or award | +5,000 | 98,804 | ||
| 2024-09-03 | Lenington Rachel COO and CDO | Grant or award | +10,000 | 23,395 | ||
| 2024-09-03 | CHURCH KEVIN CHIEF SCIENTIFIC OFFICER | Grant or award | +10,000 | 95,209 | ||
| 2024-09-03 | Worthington Mark GENERAL COUNSEL | Grant or award | +10,000 | 54,452 | ||
| 2024-09-03 | Litton Mark James President and CEO | Grant or award | +20,000 | 164,397 | ||
| 2024-06-24 | Romano Kelly A Director | Purchase | +27,400 | $2.42 | $66K | 80,715 |
| 2024-06-21 | Romano Kelly A Director | Purchase | +15,000 | $2.26 | $34K | 53,315 |
| 2024-05-24 | Romano Kelly A Director | Grant or award · Stock Option (Right to Buy) | +20,900 | 20,900 | ||
| 2024-05-24 | EDELMAN JOSEPH Director | Grant or award · Stock Option (Right to Buy) | +20,900 | 20,900 | ||
| 2024-05-24 | JOHNSON JAMES A Director | Grant or award · Stock Option (Right to Buy) | +20,900 | 20,900 | ||
| 2024-05-24 | Kosacz Barbara Director | Grant or award · Stock Option (Right to Buy) | +20,900 | 20,900 | ||
| 2024-05-24 | Panzara Michael A. Director | Grant or award · Stock Option (Right to Buy) | +20,900 | 20,900 | ||
| 2024-05-24 | PICKERING GRANT Director | Grant or award · Stock Option (Right to Buy) | +20,900 | 20,900 | ||
| 2024-05-24 | FLUKE JOHN M JR Director | Grant or award · Stock Option (Right to Buy) | +20,900 | 20,900 |
Page 8 of 10 · 187 trades